Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Renal Replacement Anticoagulant Management (RRAM)

The Renal Replacement Anticoagulant Management (RRAM) study will research the advantages and disadvantages of the two anticoagulant methods for patients with a kidney injury and treated in an ICU

Part of our ongoing collaboration with the Intensive Care National Audit and Research Centre (ICNARC), the National Institute for Health and Care Research (NIHR)-funded (16/111/136) Renal Replacement Anticoagulation Management showcases our ability to link and process large volumes of routine health data to inform patient management. The study investigated a change in practice in blood thinning to allow kidney replacement therapy in the critically ill, finding no evidence of benefit but significantly increased healthcare costs. The findings were highlighted in the NIHR publication “7 findings that could save the NHS money and improve care” and led to an NIHR alert.

RRAM Publications

Regional citrate anticoagulation versus systemic heparin anticoagulation for continuous kidney replacement therapy in intensive care 

HTA report 

For more information about the RRAM study, please visit the ICNARC website.

In this section